Trial · NCT01695187
NB-001 Treatment of Recurrent Herpes Labialis
NCT01695187, Phase 3, Unknown, NanoBio Corporation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NB-001 Treatment of Recurrent Herpes Labialis. Trials, record NCT01695187. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01695187
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NB-001 Treatment of Recurrent Herpes Labialis
- NCT number
- NCT01695187
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 362 participants, actual
- Lead sponsor
- NanoBio Corporation
- Conditions
- Herpes Labialis
- Interventions
- NB-001 (0.3%), Placebo
- First posted
- 2012-09-27
- Last updated
- 2013-06-14
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to healing of the primary lesion complex (in days or fraction thereof) as assessed by the investigator. | Time to healing will be assessed from treatment onset to resolution of symptoms (maximum of 16 days) | Time to healing is the time from receiving the combination to unlock the medication and begin treatment to investigator assessed healing. |
| Secondary | Proportion of subjects in whom the primary lesion complex does not progress beyond the Papule/Edema Stage | Proportion of subjects in whom the primary lesion complex does not progress will be assessed from treatment onset to resolution of symptoms (maximum of 16 days) | This analysis will be performed in the cohort of subjects whose primary lesion complex is assessed as being in the Prodrome (pain, burning, tingling, itching, redness, swelling, or a tight sensation of the lip), Erythema/Macule, Papule/Edema, or Aborted Stage by the investigator at the first post-treatment visit. |
| Other | Safety and tolerability | Safety and tolerability will be assessed from treatment onset to study close (expected average of 2 months) | Safety and tolerability of NB-001 following topical administration as assessed by the number and severity of adverse events. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01695187
GET https://conductscience.org/api/trials/v1/NCT01695187/registered